1 Min Read
BRUSSELS, Feb 7 (Reuters) - Medical and pharmaceutical supplies group Arseus forecast further growth of sales and profit margins in 2014, after increasing its recurring core profit by almost a third in 2013.
For 2014 the company said revenues would be at least 480 million euros ($652.8 million) with a recurring core profit margin of 26 percent. This compares with the 386 million euros revenues and a 25.4 percent margin in 2013.
The group made an overall net loss of 32 million euros in 2013, however, following several divestments of its medical supplies business over the course of the year.